Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.